Öz
Şiddetli akut solunum sendromu-koronavirüs-2 (SARS-CoV-2) enfeksiyonu çok çeşitli nörolojik ve hematolojik belirtilere neden olur. Guillain-Barre sendromu (GBS) ile başvuran ve COVID-19 enfeksiyonu sonrası hemofagositik lenfohistiyositoz (HLH) gelişen 69 yaşında Hintli erkek hasta sunulmaktadır. Hasta akut asendan paraparezi ve ateş ile başvurdu. Sinir iletim çalışmaları beyin omurilik sıvısı analizinde albümino-sitolojik ayrışma ile birlikte hem motor hem de duyu sinirlerini etkileyen aksonal dejenerasyonu ortaya çıkardı. Hastada ateş, bisitopeni, trigliserit ve ferritin düzeylerinin yüksek olması ve kemik iliği biyopsisi bulguları nedeniyle HLH düşünüldü. Hasta intravenöz immünoglobulin tedavisine iyi bir klinik yanıt vermiştir.
Anahtar Kelimeler: Guillain-Barre sendromu, hemofagositik lenfohistiyositoz, SARS-CoV-2 enfeksiyonu, hiperenflamasyon, moleküler taklit
Kaynakça
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444-8.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271-80.
Li SR, Tang ZJ, Li ZH, Liu X. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV. Eur J Clin Microbiol Infect Dis. 2020;39:1021-6.
Bader M. ACE2, angiotensin-(1-7), and Mas: the other side of the coin. Pflüg Arch. 2013;465:79-85.
Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens. 2011;20:62-8.
Pacurari M, Kafoury R, Tchounwou PB, Ndebele K. The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam. 2014;2014:689360.
Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, Scalia R, Eguchi S. Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. Physiol Rev. 2018;98:1627-738.
Hayden A, Park S, Giustini D, Lee AY, Chen LY. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review. Blood Rev. 2016;30:411-20.
Kajumba MM, Kolls BJ, Koltai DC, Kaddumukasa M, Kaddumukasa M, Laskowitz DT. COVID-19-Associated Guillain-Barre Syndrome: Atypical Para-infectious Profile, Symptom Overlap, and Increased Risk of Severe Neurological Complications. SN Compr Clin Med. 2020;2:2702-14.
Naous E, Nassani BM, Yaghi C, Nasr F, Medlej R. Hemophagocytic lymphohistiocytosis, a new cause of death during ‘post-acute COVID-19 syndrome?’ A case report. J Hematop. 2021;14:229-33.
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: surveillance and cost of treatment strategies - Authors’ reply. Lancet. 2017;389:253-4.
Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137:33-43.
La Rosée P. Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology Am Soc Hematol Educ Program. 2015;2015:190-6.
